Bipolar II disorder is a mood disorder classified within the spectrum of bipolar disorders. It is characterized by a chronic pattern of mood elevation known as hypomania, alternating with episodes of major depressive disorder. Unlike Bipolar I disorder, which includes full manic episodes, the elevated mood state in Bipolar II does not meet criteria for mania and is therefore less severe but still associated with functional impairment.
Diagnostic criteria
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‑5) specifies that a diagnosis of Bipolar II disorder requires:
- At least one lifetime episode of hypomania, defined by a distinct period of abnormally and persistently elevated, expansive, or irritable mood and increased goal‑directed activity or energy lasting at least four consecutive days, and presenting with three (or more) of the following symptoms (five if the mood is only irritable): inflated self‑esteem or grandiosity, reduced need for sleep, talkativeness, flight of ideas or subjective sense that thoughts are racing, distractibility, increased activity or psychomotor agitation, and excessive involvement in risky activities.
- At least one lifetime episode of major depressive disorder, meeting standard DSM‑5 criteria for a major depressive episode (minimum five symptoms, including depressed mood or anhedonia, present for at least two weeks).
- Absence of a full manic episode.
- The hypomanic and depressive episodes cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- The symptoms are not attributable to the physiological effects of a substance or another medical condition.
Epidemiology
Prevalence estimates for Bipolar II disorder range from 0.4 % to 1.1 % of the general population, with a slightly higher reported prevalence among women compared to men. Onset typically occurs in late adolescence or early adulthood, although cases may emerge later in life.
Clinical presentation
Patients often first seek treatment for depressive symptoms, which may be severe and recurrent. The hypomanic phases can be perceived as periods of high productivity, creativity, or reduced need for sleep, which may lead to underrecognition of the disorder. The alternating pattern contributes to a heightened risk of suicide, substance misuse, and functional decline if untreated.
Course and prognosis
The disorder is chronic and recurrent, with many individuals experiencing multiple depressive and hypomanic episodes over the lifespan. Early diagnosis and sustained treatment are associated with improved functional outcomes and reduced risk of mood episode escalation.
Treatment
Management typically involves a combination of pharmacotherapy and psychotherapy:
- Pharmacotherapy: Mood stabilizers (e.g., lithium, valproate, lamotrigine) and atypical antipsychotics (e.g., quetiapine, lurasidone) are first‑line agents. Antidepressants are generally used cautiously and often in conjunction with a mood stabilizer to mitigate the risk of triggering hypomania.
- Psychotherapy: Cognitive‑behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and psychoeducation have demonstrated efficacy in reducing relapse rates and improving adherence.
Comorbidities
High rates of comorbid psychiatric conditions are observed, including anxiety disorders, substance use disorders, attention‑deficit/hyperactivity disorder (ADHD), and personality disorders. Medical comorbidities such as cardiovascular disease and metabolic syndrome are also more prevalent, often related to lifestyle factors and medication side effects.
History
The distinction between Bipolar I and Bipolar II disorders was formalized in the DSM‑III (1980) to recognize the clinical significance of hypomanic episodes that do not meet full mania criteria. Subsequent revisions refined diagnostic thresholds and emphasized the need for careful assessment of mood polarity.
Research directions
Current investigations focus on neurobiological markers, genetic susceptibility, and the development of personalized treatment algorithms. Longitudinal studies aim to clarify trajectories of illness progression and identify predictors of treatment response.
Etymology
The term “bipolar” derives from the Latin “bi‑” (two) and “polar,” referring to the two poles of mood elevation and depression. “II” denotes the second subtype in the classification system, distinguished by the presence of hypomania rather than full mania.